Wolters Kluwer Health, a renowned technology leader in the healthcare sector, has announced the successful acquisition of Invistics Corporation (Invistics), a U.S.-based provider of cloud-based, AI-enabled software for drug diversion detection and controlled substance compliance. This strategic move aims to address the growing challenge of drug diversion in the U.S. healthcare system.
Invistics' flagship solution, Flowlytics, utilizes predictive analytics to identify instances of illicit diversion involving both controlled and non-controlled medications within patient care settings such as hospitals and ambulatory surgery centers. Drug diversion has become a pressing issue, with an estimated cost of $70 billion annually. A recent study indicates that approximately 10% to 15% of health professionals may engage in drug or alcohol misuse during their careers, further elevating the risk of drug diversion. Drug diversion occurs when healthcare workers unlawfully obtain or use prescription drugs intended for patients.
Flowlytics offers a comprehensive approach to detecting drug diversion by monitoring drug transactions from purchase to patient and employing AI algorithms to identify patterns of behavior consistent with diversion. A five-year study funded by the National Institutes of Health demonstrated that Flowlytics detected instances of drug diversion more efficiently than traditional solutions. Apart from detection capabilities, the software also supports diversion investigation, adjudication, and reporting workflows.
The acquisition of Invistics and its advanced technology aligns seamlessly with Wolters Kluwer Health's existing offerings, including Simplifi+® and Sentri7®, which aid customers in achieving optimal clinical outcomes and regulatory compliance. Incorporating Invistics' solution further strengthens the company's efforts to assist health systems in implementing effective pharmacy surveillance and compliance programs to mitigate patient risks.
Click here to read the original press release.
